Ceramide NanoLiposome in Patients with Advanced Solid Tumors

Study Name
  Ceramide NanoLiposome in Patients with Advanced Solid Tumors
ClinicalTrials.gov Identifier (if applicable)
  NCT02834611
Study Center
Institution Name
  University of Maryland, Greenebaum Cancer Center
Institution Address
  22 South Greene Street
City
  Baltimore
State
  Maryland
Zip Code
  21201
Phone
  (800) 492-5538
Website
  http://www.umm.edu/programs/cancer
List additional Institutions (include address, phone number, and website)
  Medical University of South Carolina, Hollings Cancer Center
86 Jonathan Lucas Street
Charleston, SC 29425
843-792-9300
http://www.hollingscancercenter.org/index.html

University of Virginia, Emily Couric Clinical Cancer Center
1240 Lee Street
Charlottesville, VA 22903
434-924-9333
https://uvahealth.com/locations/profile/emily-couric-clinical-cancer-center

Study Contacts
Principal Investigator
  Edward Sausville, MD, PhD
P.I. Phone
  (800) 492-5538
P.I. Email
  cheryl.young@umm.edu
List additional Principal Investigators (include phone number and email)
  Carolyn Britten, MD, Medical University of South Carolina
britten@musc.edu

Robert Dreicer, MD, UVA Cancer Center
rd7va@hscmail.mcc.virginia.edu
434-982-4798

Study Coordinator
  Cheryl Young, University of Maryland
Study Coordinator Phone
  (410) 328-8611
Study Coordinator Email
  cheryl.young@umm.edu
List additional Study Coordinators (include phone number and email)
  Alan Brisendine, Medical University of South Carolina
843-792-9007
brisend@musc.edu

Sue Jones, University of Virginia
434-924-9199
syt8a@virginia.edu

OVERVIEW – in layman’s terms (150 words max)
  This study is a dose escalation study to determine the safety and tolerability of Ceramide NanoLiposome in patients with advanced solid tumors.
Enrollment
  18-48
Study Start Date
  03/28/2017
Estimated Completion Date
  09/28/2018

Pin It on Pinterest